Understanding metastasis in pancreatic cancer: a call for new clinical approaches, Cell, vol.148, pp.21-24, 2012. ,
Other radiopharmaceuticals for imaging GEP-NET, Somatostatin analogues: from research to clinical practice, 2015. ,
Molecular imaging in pancreatic cancer-a roadmap for therapeutic decisions, Cancer Lett, vol.341, pp.132-140, 2013. ,
Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science, vol.359, pp.926-956, 2018. ,
MRI with hyperpolarised [1-13C]pyruvate detects advanced pancreatic preneoplasia prior to invasive disease in a mouse model, Gut, vol.65, pp.465-75, 2016. ,
p53 status determines the role of autophagy in pancreatic tumour development, Nature, vol.504, pp.296-300, 2013. ,
The role of 18F-FDG PET/CT and PET/MRI in pancreatic ductal adenocarcinoma, Abdom Radiol (NY), vol.43, pp.415-449, 2018. ,
Pancreatic adenocarcinoma: ESMOESDO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.23, issue.7, pp.33-40, 2012. ,
Pancreatic cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann Oncol, vol.21, issue.5, pp.55-63, 2010. ,
PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-glucose positron emission tomography with computed tomography scanning in the diagnosis and management of pancreatic cancer, Health Technol Assess, vol.22, pp.1-114, 2018. ,
FDG PET/CT findings in malignant intraductal papillary mucinous neoplasm of the bile ducts, Clin Nucl Med, vol.35, pp.83-88, 2010. ,
Pancreatic cancer: FDG-PET is not useful in early pancreatic cancer diagnosis, Nat Rev Gastroenterol Hepatol, vol.10, pp.203-208, 2013. ,
Zr-anti-gammaH2AX-TAT but not (18)F-FDG allows early monitoring of response to chemotherapy in a mouse model of pancreatic ductal adenocarcinoma, Clin Cancer Res, vol.89, pp.6498-504, 2017. ,
Correlation of (18)F-Fluorodeoxyglucose positron emission tomography parameters with patterns of disease progression in locally advanced pancreatic cancer after definitive chemoradiotherapy, Clin Oncol ® Coll Radiol), vol.29, pp.370-377, 2017. ,
State-of-the-art PET/CT of the pancreas: current role and emerging indications, Radiographics, vol.32, pp.1133-58, 2012. ,
18F-FLT PET imaging of cellular proliferation in pancreatic cancer, Crit Rev Oncol Hematol, vol.99, pp.158-69, 2016. ,
3?-Deoxy-3?-18F-fluorothymidine positron emission tomography as an early predictor of disease progression in ,
, Med Mol Imaging patients with advanced and metastatic pancreatic cancer, Eur J Nucl Med Mol Imaging, vol.42, pp.831-871, 2015.
Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer, Eur J Nucl Med Mol Imaging, vol.35, pp.527-558, 2008. ,
)F-fluorothymidine PET for predicting survival in patients with resectable pancreatic cancer, Oncotarget, vol.9, issue.18, pp.10128-10162, 2018. ,
The impact of hypoxia in pancreatic cancer invasion and metastasis, Hypoxia (Auckl), vol.2, pp.91-106, 2014. ,
Desmoplasia of pancreatic ductal adenocarcinoma, Clin Gastroenterol Hepatol, vol.7, pp.44-51, 2009. ,
ARCII: a phase II trial of the HIV protease inhibitor nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer, Radiother Oncol, vol.119, pp.306-317, 2016. ,
Measurement of tumor hypoxia in patients with advanced pancreatic cancer based on 18F-fluoroazomyin arabinoside uptake, J Nucl Med, vol.57, pp.361-367, 2016. ,
Detection of hypoxia with 18F-fluoromisonidazole (18FFMISO) PET/CT in suspected or proven pancreatic cancer, Clin Nucl Med, vol.38, pp.1-6, 2013. ,
Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer, Radiother Oncol, vol.116, pp.94-103, 2015. ,
Radioimmunodetection with 111In-labelled monoclonal antibody Nd2 in patients with pancreatic cancer, Jpn J Cancer Res, vol.88, pp.427-461, 1997. ,
Molecular imaging of pancreatic cancer with antibodies, Mol Pharm, vol.13, pp.8-24, 2016. ,
Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging, Oncotarget, vol.6, pp.4496-504, 2015. ,
Molecular imaging in drug development: update and challenges for radiolabeled antibodies and nanotechnology, Methods, vol.130, pp.23-35, 2017. ,
Site-specifically labeled immunoconjugates for molecular imaging-part 1: cysteine residues and glycans, Mol Imaging Biol, vol.18, pp.1-17, 2016. ,
The prognostic role of desmoplastic stroma in pancreatic ductal adenocarcinoma, Oncotarget, vol.7, pp.4183-94, 2016. ,
Claudin-4-targeted optical imaging detects pancreatic cancer and its precursor lesions, Gut, vol.62, pp.1034-1077, 2013. ,
The inflammatory milieu within the pancreatic cancer microenvironment correlates with clinicopathologic parameters, chemoresistance and survival, BMC Cancer, vol.15, p.783, 2015. ,
Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma, Oncotarget, vol.8, pp.56816-56844, 2017. ,
Aberrant signaling pathways in pancreatic cancer: a two compartment view, Mol Carcinog, vol.51, pp.25-39, 2012. ,
Oncogenic KRAS signalling in pancreatic cancer, Br J Cancer, vol.111, pp.817-839, 2014. ,
Activation of WNT/beta-catenin signaling enhances pancreatic cancer development and the malignant potential via up-regulation of Cyr61, Neoplasia, vol.18, pp.785-94, 2016. ,
Notch signaling in pancreatic cancer: oncogene or tumor suppressor?, Trends Mol Med, vol.19, pp.320-327, 2013. ,
GRP78: a multifunctional receptor on the cell surface, Antioxid Redox Signal, vol.11, pp.2299-306, 2009. ,
A critical role for GRP78/BiP in the tumor microenvironment for neovascularization during tumor growth and metastasis, Cancer Res, vol.71, pp.2848-57, 2011. ,
Beyond the endoplasmic reticulum: atypical GRP78 in cell viability, signalling and therapeutic targeting, Biochem J, vol.434, pp.181-189, 2011. ,
Cell surface GRP78, a new paradigm in signal transduction biology, 2018. ,
Monoclonal antibody against cell surface GRP78 as a novel agent in suppressing PI3K/AKT signaling, tumor growth, and metastasis, Clin Cancer Res, vol.19, pp.6802-6813, 2013. ,
Smallanimal PET imaging of pancreatic cancer xenografts using a 64Culabeled monoclonal antibody, MAb159, J Nucl Med, vol.56, pp.908-921, 2015. ,
Transferrin receptor 1: a target for antibody-mediated cancer therapy, Immunotherapy, vol.8, pp.991-995, 2016. ,
Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas, Eur J Cancer, vol.40, pp.1418-1440, 2004. ,
Transferrin receptor regulates pancreatic cancer growth by modulating mitochondrial respiration and ROS generation, Biochem Biophys Res Commun, vol.471, pp.373-382, 2016. ,
Imaging tumor burden in the brain with 89Zr-transferrin, J Nucl Med, vol.54, pp.90-95, 2013. ,
, Eur J Nucl Med Mol Imaging
Annotating MYC status with 89Zr-transferrin imaging, Nat Med, vol.18, pp.1586-91, 2012. ,
A tumor-targeted nanodelivery system to improve early MRI detection of cancer, Mol Imaging, vol.5, pp.41-52, 2006. ,
Preclinical evaluation of 89Zr-labeled human antitransferrin receptor monoclonal antibody as a PET probe using a pancreatic cancer mouse model, Nucl Med Commun, vol.36, pp.286-94, 2015. ,
Clinical significance of mesothelin in pancreatic cancer, Curr Signal Transduct Ther, vol.11, pp.9-12, 2016. ,
Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE), Clin Cancer Res, vol.7, pp.3862-3870, 2001. ,
Mesothelin immunotherapy for cancer: ready for prime time?, J Clin Oncol, vol.34, pp.4171-4180, 2016. ,
ImmunoPET with antimesothelin antibody in patients with pancreatic and ovarian cancer before anti-mesothelin antibody-drug conjugate treatment, Clin Cancer Res, vol.22, pp.1642-52, 2016. ,
Proteomics. Tissue-based map of the human proteome, Science, vol.347, p.1260419, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01479709
First-in-human study of (89)Zr-DFOHuMab-5B1 (MVT-2163) PET/CT imaging with and without HuMab-5B1 (MVT-5873) in patients with pancreatic cancer and other CA 19-9 positive malignancies, J Nucl Med, vol.58, p.385, 2017. ,
Radiolabelled RGD peptides for imaging and therapy, Eur J Nucl Med Mol Imaging, vol.39, issue.1, pp.126-164, 2012. ,
Molecular imaging of integrins in oncology, Rep Med Imaging, vol.10, pp.17-30, 2017. ,
Perspective of alphavbeta6-integrin imaging for clinical management of pancreatic carcinoma and its precursor lesions, Mol Imaging, vol.16, p.1536012117709384, 2017. ,
A human monoclonal antibody 264RAD targeting alphavbeta6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivo, Oncogene, vol.32, pp.4406-4422, 2013. ,
The integrin ?v?6 is a promising target for the therapy of PDAC: toward phase I trials, Pancreatology, vol.3, p.14, 2014. ,
Perspective of ?v?6-integrin imaging for clinical management of pancreatic carcinoma and its precursor lesions, Mol Imaging, vol.16, pp.1-3, 2017. ,
Multimodal molecular imaging of integrin alphavbeta3 for in vivo detection of pancreatic cancer, J Nucl Med, vol.55, pp.446-51, 2014. ,
Expression of tissue factor in pancreatic adenocarcinoma is associated with activation of coagulation, World J Gastroenterol, vol.12, pp.4843-4852, 2006. ,
ImmunoPET imaging of tissue factor expression in pancreatic cancer with (89)Zr-Df-ALT-836, J Control Release, vol.264, pp.160-168, 2017. ,
Immuno-PET of tissue factor in pancreatic cancer, J Nucl Med, vol.53, pp.1748-54, 2012. ,
Molecular imaging using an anti-human tissue factor monoclonal antibody in an orthotopic glioma xenograft model, Sci Rep, vol.7, p.12341, 2017. ,
The isolation of a new hypotensive peptide, neurotensin, from bovine hypothalami, J Biol Chem, vol.248, pp.6854-61, 1973. ,
Neurotensin receptors in pancreatic ductal carcinomas, EJNMMI Res, vol.5, p.17, 2015. ,
18)Fand (68)Ga-labeled neurotensin peptides for PET imaging of neurotensin receptor 1, J Med Chem, vol.59, pp.6480-92, 2016. ,
Synthesis and evaluation of a (18)F-labeled diarylpyrazole glycoconjugate for the imaging of NTS1-positive tumors, J Med Chem, vol.56, pp.9361-9366, 2013. ,
Cathepsins and pancreatic cancer: the 2012 update, Pancreatology, vol.12, pp.395-401, 2012. ,
Detection of pancreatic cancer tumours and precursor lesions by cathepsin E activity in mouse models, Gut, vol.61, pp.1315-1337, 2012. ,
Non-invasive in vivo imaging of tumour-associated cathepsin B by a highly selective inhibitory DARPin, Theranostics, vol.7, pp.2806-2827, 2017. ,
Cathepsin B promotes the progression of pancreatic ductal adenocarcinoma in mice, Gut, vol.61, pp.877-84, 2012. ,
Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort, Onco Targets Ther, vol.10, pp.1199-206, 2017. ,
Preclinical evaluation of a novel CEA-targeting near-infrared fluorescent tracer delineating colorectal and pancreatic tumors, Int J Cancer, vol.137, pp.1910-1930, 2015. ,
Correlation between preoperative serum carcinoembryonic antigen levels and expression on pancreatic and rectal cancer tissue, Biomark Cancer, vol.9, 2017. ,
Development of an imagingguided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results, Br J Cancer, vol.109, pp.934-976, 2013. ,
, Eur J Nucl Med Mol Imaging
Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting, Proc Natl Acad Sci, vol.103, pp.6841-6847, 2006. ,
Multifunctional antibodies by the dock-and-lock method for improved cancer imaging and therapy by pretargeting, J Nucl Med, vol.49, pp.158-63, 2008. ,
Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice, J Nucl Med, vol.51, pp.1780-1787, 2010. ,
Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/ NIRF imaging of pancreatic cancer, Proc Natl Acad Sci U S A, vol.112, pp.15850-15855, 2015. ,
Preloading with unlabeled CA19.9 targeted human monoclonal antibody leads to improved PET imaging with (89)Zr-5B1, Mol Pharm, vol.14, pp.908-923, 2017. ,
The pancreas cancer microenvironment, Clin Cancer Res, vol.18, pp.4266-76, 2012. ,
Noninvasive prediction of tumor responses to gemcitabine using positron emission tomography, Proc Natl Acad Sci, vol.106, issue.8, pp.2847-2852, 2009. ,
In vitro and in vivo comparison of gemcitabine and the gemcitabine analog 1-(2?-deoxy-2?fluoroarabinofuranosyl) cytosine (FAC) in human orthotopic and genetically modified mouse pancreatic cancer models, Mol Imaging Biol, vol.19, pp.885-92, 2017. ,
Epithelial uptake of [18F]1-(2?-deoxy-2?-arabinofuranosyl) cytosine indicates intestinal inflammation in mice, Gastroenterology, vol.138, pp.1266-75, 2010. ,
Imaging biomarker roadmap for cancer studies, Nat Rev Clin Oncol, vol.14, pp.169-86, 2017. ,
Genetically engineered mouse models of pancreatic cancer, Cancer J, vol.18, pp.502-512, 2012. ,
Carbonic anhydrase activity monitored in vivo by hyperpolarized 13C-magnetic resonance spectroscopy demonstrates its importance for pH regulation in tumors, Cancer Res, vol.75, pp.4109-4127, 2015. ,
Detection of precursor lesions of pancreatic adenocarcinoma in PET-CT in a genetically engineered mouse model of pancreatic cancer, Neoplasia, vol.13, pp.180-186, 2011. ,
Patient-derived xenograft models: an emerging platform for translational cancer research, Cancer Discov, vol.4, pp.998-1013, 2014. ,
Pancreatic ductal adenocarcinoma: current and evolving therapies, Int J Mol Sci, vol.18, p.1338, 2017. ,